[微笑]_老虎社区_美港股上老虎

may_bb
2021-06-10

[微笑]

AEMD Stock: The Historic Covid-19 News Sending Aethlon Medical Rocketing 388%

Shares of Aethlon Medical(NASDAQ:AEMD) stock are blasting off on Wednesday after major news emerged

AEMD Stock: The Historic Covid-19 News Sending Aethlon Medical Rocketing 388%

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":189797102,"tweetId":"189797102","gmtCreate":1623287968006,"gmtModify":1634034953791,"author":{"id":3581758336143094,"idStr":"3581758336143094","authorId":3581758336143094,"authorIdStr":"3581758336143094","name":"may_bb","avatar":"https://static.tigerbbs.com/d7bdcb7e740e6a76cca3ed15f2bc52b4","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":8,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p><span>[微笑]&nbsp;</span></p></body></html>","htmlText":"<html><head></head><body><p><span>[微笑]&nbsp;</span></p></body></html>","text":"[微笑]","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/189797102","repostId":1168166668,"repostType":4,"repost":{"id":"1168166668","pubTimestamp":1623281394,"share":"https://www.laohu8.com/m/news/1168166668?lang=&edition=full","pubTime":"2021-06-10 07:29","market":"us","language":"en","title":"AEMD Stock: The Historic Covid-19 News Sending Aethlon Medical Rocketing 388%","url":"https://stock-news.laohu8.com/highlight/detail?id=1168166668","media":"investorplace","summary":"Shares of Aethlon Medical(NASDAQ:AEMD) stock are blasting off on Wednesday after major news emerged ","content":"<p>Shares of&nbsp;<b>Aethlon Medical</b>(NASDAQ:<b><u>AEMD</u></b>) stock are blasting off on Wednesday after major news emerged from the company last week regarding the fight against the novel coronavirus.</p>\n<p>Aethlon Medical shared results last Thursday fortwo patients with Covid-19that were treated with the company’s Hemopurifier. According to the release, this is “a cartridge that is designed to filter viruses and exosomes from the blood.” In turn, the patients were treated over a total of nine sessions, and both showed improvements in their condition.</p>\n<p>Moreover, the Hemopurifier is designated as a“Breakthrough Device”by the U.S. Food and Drug Administration (FDA) for treating metastatic cancer. Now, the tool is now closely being looked at by the FDA through an early feasibility study.</p>\n<p>Charles J. Fisher, Jr., CEO of Aethlon Medical, said this about the AEMD stock news.</p>\n<blockquote>\n “The COVID-19 pandemic has affected the world over, prompting the need for innovative treatment approaches. We believe that the Hemopurifier® is such an innovation, as it is the only known device that can filter out exosomes, which are thought to play a role in the severity of infectious diseases like COVID-19. … These two case studies indicate that the Hemopurifier® was successfully able to clear SARS-CoV-2 virus and associated exosomes from the blood stream, resulting in a potential benefit for one of the critical COVID-19 patients that were treated.”\n</blockquote>\n<p>AEMD stock was up&nbsp;388% as of Wednesday afternoon.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AEMD Stock: The Historic Covid-19 News Sending Aethlon Medical Rocketing 388%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAEMD Stock: The Historic Covid-19 News Sending Aethlon Medical Rocketing 388%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-10 07:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/aemd-stock-the-historic-covid-19-news-sending-aethlon-medical-rocketing-350/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Aethlon Medical(NASDAQ:AEMD) stock are blasting off on Wednesday after major news emerged from the company last week regarding the fight against the novel coronavirus.\nAethlon Medical shared...</p>\n\n<a href=\"https://investorplace.com/2021/06/aemd-stock-the-historic-covid-19-news-sending-aethlon-medical-rocketing-350/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AEMD":"Aethlon Medical Inc"},"source_url":"https://investorplace.com/2021/06/aemd-stock-the-historic-covid-19-news-sending-aethlon-medical-rocketing-350/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1168166668","content_text":"Shares of Aethlon Medical(NASDAQ:AEMD) stock are blasting off on Wednesday after major news emerged from the company last week regarding the fight against the novel coronavirus.\nAethlon Medical shared results last Thursday fortwo patients with Covid-19that were treated with the company’s Hemopurifier. According to the release, this is “a cartridge that is designed to filter viruses and exosomes from the blood.” In turn, the patients were treated over a total of nine sessions, and both showed improvements in their condition.\nMoreover, the Hemopurifier is designated as a“Breakthrough Device”by the U.S. Food and Drug Administration (FDA) for treating metastatic cancer. Now, the tool is now closely being looked at by the FDA through an early feasibility study.\nCharles J. Fisher, Jr., CEO of Aethlon Medical, said this about the AEMD stock news.\n\n “The COVID-19 pandemic has affected the world over, prompting the need for innovative treatment approaches. We believe that the Hemopurifier® is such an innovation, as it is the only known device that can filter out exosomes, which are thought to play a role in the severity of infectious diseases like COVID-19. … These two case studies indicate that the Hemopurifier® was successfully able to clear SARS-CoV-2 virus and associated exosomes from the blood stream, resulting in a potential benefit for one of the critical COVID-19 patients that were treated.”\n\nAEMD stock was up 388% as of Wednesday afternoon.","news_type":1},"isVote":1,"tweetType":1,"viewCount":426,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":6,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}